OBJECTIVE: Hypofractionated radiotherapy in early stage breast cancer is an effective adjuvant treatment, but there is a lack of randomized data for patients with ductal carcinoma in situ (DCIS). The aim of this study is the evaluation of skin toxicity and cosmesis, and early clinical outcome of DCIS patients enrolled in an institutional Phase II trial of hypofractionated breast irradiation. METHODS: 137 DCIS patients were enrolled in the trial. All patients underwent volumetric modulated arc therapy (VMAT) to the whole breast with a total dose of 40.5 Gy in 15 fractions over 3 weeks, without tumour bed boost. Acute and late skin toxicities were recorded. Cosmetic outcomes were assessed as excellent/good or fair/poor. Early clinical outcome was reported. RESULTS: Median age was 58 y.o. (range 30-86). The median follow-up time was 22 months (range 6-45). At the end of the radiotherapy, skin toxicity was grade G1 in 56% of the patients, G2 in 15%, no patients presented G3 toxicity. In the range of 3-9 months of follow-up, the skin toxicity was G1 in 28% of patients, no G2-G3 cases; cosmetic outcome was good/excellent in 95% of patients. In the follow-up interval of 9-24 months, the skin toxicity was G1 in 12% of patients, no G2-G3 toxicity; cosmetic outcome was good/excellent in 96% of patients. After an early evaluation of clinical outcomes, 5 patients (3.6%) presented an in-breast recurrence. CONCLUSION: Hypofractionated radiotherapy using VMAT is a viable option for DCIS. A longer follow-up is needed to assess clinical outcomes and late toxicity. Advances in knowledge: The use of hypofractionated VMAT is dosimetrically feasible for treating breast DCIS.
OBJECTIVE: Hypofractionated radiotherapy in early stage breast cancer is an effective adjuvant treatment, but there is a lack of randomized data for patients with ductal carcinoma in situ (DCIS). The aim of this study is the evaluation of skin toxicity and cosmesis, and early clinical outcome of DCIS patients enrolled in an institutional Phase II trial of hypofractionated breast irradiation. METHODS: 137 DCIS patients were enrolled in the trial. All patients underwent volumetric modulated arc therapy (VMAT) to the whole breast with a total dose of 40.5 Gy in 15 fractions over 3 weeks, without tumour bed boost. Acute and late skin toxicities were recorded. Cosmetic outcomes were assessed as excellent/good or fair/poor. Early clinical outcome was reported. RESULTS: Median age was 58 y.o. (range 30-86). The median follow-up time was 22 months (range 6-45). At the end of the radiotherapy, skin toxicity was grade G1 in 56% of the patients, G2 in 15%, no patients presented G3 toxicity. In the range of 3-9 months of follow-up, the skin toxicity was G1 in 28% of patients, no G2-G3 cases; cosmetic outcome was good/excellent in 95% of patients. In the follow-up interval of 9-24 months, the skin toxicity was G1 in 12% of patients, no G2-G3 toxicity; cosmetic outcome was good/excellent in 96% of patients. After an early evaluation of clinical outcomes, 5 patients (3.6%) presented an in-breast recurrence. CONCLUSION: Hypofractionated radiotherapy using VMAT is a viable option for DCIS. A longer follow-up is needed to assess clinical outcomes and late toxicity. Advances in knowledge: The use of hypofractionated VMAT is dosimetrically feasible for treating breast DCIS.
Authors: B Fisher; J Dignam; N Wolmark; E Mamounas; J Costantino; W Poller; E R Fisher; D L Wickerham; M Deutsch; R Margolese; N Dimitrov; M Kavanah Journal: J Clin Oncol Date: 1998-02 Impact factor: 44.544
Authors: I Meattini; L Livi; D Franceschini; C Saieva; F Meacci; L Marrazzo; B Bendinelli; V Scotti; C De Luca Cardillo; J Nori; L Sanchez; L Orzalesi; P Bonomo; D Greto; M Bucciolini; S Bianchi; G Biti Journal: Eur J Surg Oncol Date: 2013-03-20 Impact factor: 4.424
Authors: Kimberley S Mak; Yu-Hui Chen; Paul J Catalano; Rinaa S Punglia; Julia S Wong; Linh Truong; Jennifer R Bellon Journal: Int J Radiat Oncol Biol Phys Date: 2014-07-29 Impact factor: 7.038
Authors: Raquel Ciervide; Shubhada Dhage; Amber Guth; Richard L Shapiro; Deborah M Axelrod; Daniel F Roses; Silvia C Formenti Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-01 Impact factor: 7.038
Authors: Meena S Moran; Yinjun Zhao; Shuangge Ma; Youlia Kirova; Alain Fourquet; Peter Chen; Karen Hoffman; Kelly Hunt; Julia Wong; Lia M Halasz; Gary Freedman; Robert Prosnitz; Michael Yassa; David H A Nguyen; Tarek Hijal; Bruce G Haffty; Elaine S Wai; Pauline T Truong Journal: JAMA Oncol Date: 2017-08-01 Impact factor: 33.006
Authors: Jack Cuzick; Ivana Sestak; Sarah E Pinder; Ian O Ellis; Sharon Forsyth; Nigel J Bundred; John F Forbes; Hugh Bishop; Ian S Fentiman; William D George Journal: Lancet Oncol Date: 2010-12-07 Impact factor: 41.316
Authors: Icro Meattini; Marta Scorsetti; Fiorenza De Rose; Maria Carmen De Santis; Bruno Meduri; Ciro Franzese; Davide Franceschini; Pierfrancesco Franco; Nadia Pasinetti; Valentina Lancellotta; Patrizia Giacobazzi; Eliana La Rocca; Elisa D'Angelo; Laura Lozza; Lorenzo Livi Journal: J Cancer Res Clin Oncol Date: 2021-01-02 Impact factor: 4.553
Authors: Simona F Shaitelman; Xiudong Lei; Alastair Thompson; Pamela Schlembach; Elizabeth S Bloom; Isidora Y Arzu; Daniel Buchholz; Gregory Chronowski; Tomas Dvorak; Emily Grade; Karen Hoffman; George Perkins; Valerie K Reed; Shalin J Shah; Michael C Stauder; Eric A Strom; Welela Tereffe; Wendy A Woodward; Diana N Amaya; Yu Shen; Gabriel N Hortobagyi; Kelly K Hunt; Thomas A Buchholz; Benjamin D Smith Journal: J Clin Oncol Date: 2018-10-31 Impact factor: 44.544